Legal & General Group’s Juno Therapeutics, Inc. JUNO Stock Holding History

Legal & General Group’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-225,251	Closed	-$10.3M	–	3304
2017 Q4	$10.3M	Buy	225,251 +200,178	+798%	+$9.99M	0.01%	801
2017 Q3	$1.13M	Buy	25,073 +2,294	+10%	+$78.2K	﹤0.01%	1815
2017 Q2	$681K	Sell	22,779 -3,079	-12%	-$76K	﹤0.01%	1967
2017 Q1	$574K	Buy	25,858 +17,792	+221%	+$382K	﹤0.01%	2000
2016 Q4	$152K	Buy	8,066 +863	+12%	+$21.1K	﹤0.01%	2337
2016 Q3	$216K	Buy	7,203 +1,733	+32%	+$53.9K	﹤0.01%	2003
2016 Q2	$210K	Buy	5,470 +306	+6%	+$12.7K	﹤0.01%	1751
2016 Q1	$197K	Buy	5,164 +1,192	+30%	+$41.5K	﹤0.01%	1744
2015 Q4	$175K	Buy	3,972 +592	+18%	+$29.4K	﹤0.01%	1799
2015 Q3	$138K	Buy	+3,380	New	+$148K	﹤0.01%	1873

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Legal & General Group's JUNO Position: Q1 2018 in Review

Legal & General Group sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 225,251 shares — an estimated $10.3M sold.

Legal & General Group first reported a position in JUNO in Q3 2015 and held it in 10 quarters. The position peaked at $10.3M in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

Legal & General Group reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Legal & General Group sold 225,251 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $10.3M.
Legal & General Group first reported a position in Juno Therapeutics, Inc. in Q3 2015 and held it in 10 quarters.
Legal & General Group's Juno Therapeutics, Inc. position peaked at $10.3M in Q4 2017.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Legal & General Group's 13F filing for Q1 2018, filed 17 May 2018.